The 36-month beta value for CTXR is also noteworthy at 1.64. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CTXR is 168.40M, and at present, short sellers hold a 7.58% of that float. The average trading volume of CTXR on October 24, 2024 was 1.44M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CTXR) stock’s latest price update
Citius Pharmaceuticals Inc (NASDAQ: CTXR) has experienced a decline in its stock price by -1.68 compared to its previous closing price of 0.36. However, the company has seen a fall of -14.37% in its stock price over the last five trading days. prnewswire.com reported 2024-09-05 that CEO Leonard Mazur to present on Tuesday, September 10, 2024, at 9:00 am ET CRANFORD, N.J., Sept. 5, 2024 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), today announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at the H.C.
CTXR’s Market Performance
Citius Pharmaceuticals Inc (CTXR) has seen a -14.37% fall in stock performance for the week, with a -32.00% decline in the past month and a -63.43% plunge in the past quarter. The volatility ratio for the week is 9.82%, and the volatility levels for the past 30 days are at 9.39% for CTXR. The simple moving average for the past 20 days is -14.23% for CTXR’s stock, with a -48.10% simple moving average for the past 200 days.
Analysts’ Opinion of CTXR
Many brokerage firms have already submitted their reports for CTXR stocks, with Maxim Group repeating the rating for CTXR by listing it as a “Buy.” The predicted price for CTXR in the upcoming period, according to Maxim Group is $4 based on the research report published on November 30, 2021 of the previous year 2021.
CTXR Trading at -29.58% from the 50-Day Moving Average
After a stumble in the market that brought CTXR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.19% of loss for the given period.
Volatility was left at 9.39%, however, over the last 30 days, the volatility rate increased by 9.82%, as shares sank -29.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.64% lower at present.
During the last 5 trading sessions, CTXR fell by -11.68%, which changed the moving average for the period of 200-days by -51.49% in comparison to the 20-day moving average, which settled at $0.4099. In addition, Citius Pharmaceuticals Inc saw -53.59% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CTXR
The total capital return value is set at -0.44. Equity return is now at value -41.76, with -36.91 for asset returns.
Based on Citius Pharmaceuticals Inc (CTXR), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -90.9. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -10.01.
Currently, EBITDA for the company is -36.54 million with net debt to EBITDA at 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.75.
Conclusion
In summary, Citius Pharmaceuticals Inc (CTXR) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
